ReviewCurrent opinion in genetics & development2021
Insights into clonal hematopoiesis and its relation to cancer risk.
Review in Current opinion in genetics & development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Bone marrow failure syndromes across the age spectrum: diagnostic and therapeutic principles.EClinicalMedicine · 2026Review
- Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.Nature medicine · 2025Article
- Review
- Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.Gynecologic oncology · 2024Article
- How we manage multiple myeloma with clonal hematopoiesis of indeterminate potential (CHIP): a case report.Annals of translational medicine · 2024Article
- Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis.Cancer discovery · 2024Article
- Variation in cancer risk between organs can not be explained by the degree of somatic clonal expansion.Advanced biotechnology · 2024Article
- Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders.Current hematologic malignancy reports · 2024Review
- Methods for Estimating Personal Disease Risk and Phylogenetic Diversity of Hematopoietic Stem Cells.Molecular biology and evolution · 2024Article
- Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis.medRxiv : the preprint server for health sciences · 2023Article
- NLRP3 and cancer: Pathogenesis and therapeutic opportunities.Pharmacology & therapeutics · 2023Review
- Cannabis- and Substance-Related Carcinogenesis in Europe: A Lagged Causal Inferential Panel Regression Study.Journal of xenobiotics · 2023Article
- Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation.Cancer discovery · 2022Article
- Review
- Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease.Diagnostics (Basel, Switzerland) · 2022Review
- Epidemiology of Δ8THC-Related Carcinogenesis in USA: A Panel Regression and Causal Inferential Study.International journal of environmental research and public health · 2022Article
- Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders.Current hematologic malignancy reports · 2022Review
- Increasing Complexity of Molecular Landscapes in Human Hematopoietic Stem and Progenitor Cells during Development and Aging.International journal of molecular sciences · 2022Review
- Distinction of lymphoid and myeloid clonal hematopoiesis.Nature medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
In the multi-hit model of carcinogenesis, a precancerous state often precedes overt malignancy. Identification of these states has been of great interest as they allow for early identification of at-risk individuals before the appearance of a future cancer. One such condition has recently been described for blood cancers: Clonal Hematopoiesis of Indeterminate Potential (CHIP). Recent research advances have elucidated the risk of progression of CHIP to myeloid malignancies, its potential as a precursor for non-myeloid blood cancers, and its association with non-hematological cancers. Understanding the evolution of CHIP to hematological malignancy may help identify CHIP carriers at high risk of transformation and lead to the development of targeted therapies that can be deployed preemptively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.